EPCAM and renal cell carcinoma: We demonstrated a 181% increase of capture efficiency of cytologically validated CTCs in 2 mL blood when CA9 and CD147 were used in combination as capture antigens in comparison with EpCAM antigen (p<0.001, Figure 3B), which was consistent with the observations made by IHC in clinical RCC samples.